ClotBlog - News on venous thromboembolism & anticoagulation management http://blogs.theheart.org/clot-blog Dr Samuel Goldhaber from Harvard Medical School and the Brigham and Women's Hospital discussing venous thromboembolism and anticoagulation management. Cardiologist and professor, Dr Samuel Goldhaber, Harvard Medical School and Brigham and Women's Hospital, animates this forum on venous thromboembolism and anticoagulation management. en-us theheart.org theheart.org info@theheart.org http://blogs.theheart.org/images/clot-blog/rss_banner_url.jpg Cardiologist and professor, Dr Samuel Goldhaber, Harvard Medical School and Brigham and Women's Hospital, animates this forum on venous thromboembolism and anticoagulation management. http://blogs.theheart.org/clot-blog Should we prescribe novel anticoagulants or warfarin as first line agents for stroke prevention in... Clotblog with Dr Samuel Goldhaber info@theheart.org It's been hotly debated on the pages of Circulation (and beyond). How has your approach to stroke prevention in atrial fibrillation changed with the advent of new oral anticoagulants?<img src="http://feeds.feedburner.com/~r/clot-blog/~4/raEVL2ZqOKU" height="1" width="1"/> It's been hotly debated on the pages of Circulation (and beyond). How has your approach to stroke prevention in atrial fibrillation changed with the advent of new oral anticoagulants?

See also:

Granger CB, Armaganigan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 2012; 125:159-164. Available here.

Ansell J. Newer oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2012; 125:165-170. Available here.

]]> Sun, 06 May 2012 13:25:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/raEVL2ZqOKU/should-we-prescribe-novel-anticoagulants-or-warfarin-as-first-line-agents-for http://blogs.theheart.org/clot-blog/2012/5/2/should-we-prescribe-novel-anticoagulants-or-warfarin-as-first-line-agents-for http://blogs.theheart.org/clot-blog/2012/5/2/should-we-prescribe-novel-anticoagulants-or-warfarin-as-first-line-agents-for#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/should-we-prescribe-novel-anticoagulants-or-warfarin-as-first-line-agents-for.jpg 3 http://blogs.theheart.org/clot-blog/2012/5/2/should-we-prescribe-novel-anticoagulants-or-warfarin-as-first-line-agents-for Recent PE thrombolysis trials: MAPPET, MOPETT, and MUPPET, with Dr Stavros Konstantinides Clotblog with Dr Samuel Goldhaber info@theheart.org Dr Sam Goldhaber catches up with Dr Stavros Konstantinides for a comprehensive review of the important trials on PE thrombolysis and a discussion of what direction future research will take.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/J8Qh7kNLQAA" height="1" width="1"/> Dr Sam Goldhaber catches up with Dr Stavros Konstantinides for a comprehensive review of the important trials on PE thrombolysis and a discussion of what direction future research will take.

See also:

MAPPET 1 registry of "major" PE:

Kasper W, Konstantinides S, Geibel A. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997;30:1165-1171. Available here.

Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997; 96:882-8. Available here.

MAPPET 2 cohort study on biomarkers in PE:

Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002; 106:1263-8. Available here.

MAPPET-3 trial:

Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347:1143-50. Available here.

Stein PD, Matta F, Steinberger DS, et al. Intracerebral hemorrage with thrombolytic therapy for acute pulmonary embolism. Am J Med 2012; 125:50-56. Abstract.

Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: Saves lives but underused. Am J Med 2012; 125:465-470. Abstract.

All about Pulmonary Embolism: Assessing Risk, Managing Patients

]]> Fri, 27 Apr 2012 11:55:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/J8Qh7kNLQAA/recent-pe-thrombolysis-trials--mappet-mopett-and-muppet-with-dr-stavros-konstantinides http://blogs.theheart.org/clot-blog/2012/4/27/recent-pe-thrombolysis-trials--mappet-mopett-and-muppet-with-dr-stavros-konstantinides http://blogs.theheart.org/clot-blog/2012/4/27/recent-pe-thrombolysis-trials--mappet-mopett-and-muppet-with-dr-stavros-konstantinides#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/recent-pe-thrombolysis-trials--mappet-mopett-and-muppet-with-dr-stavros-konstantinides.jpg 0 http://blogs.theheart.org/clot-blog/2012/4/27/recent-pe-thrombolysis-trials--mappet-mopett-and-muppet-with-dr-stavros-konstantinides The US Postal Service promotes heart health Clotblog with Dr Samuel Goldhaber info@theheart.org The USPS is to be commended for its attractive new stamp and six practical, commonsense tips to promote a healthy heart.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/VkRzO-5apms" height="1" width="1"/> The USPS is to be commended for its attractive new stamp and six practical, commonsense tips to promote a healthy heart.

See also:

Surgeon general joins 2012 social awareness stamp dedication

Liu K, Daviglus ML, Loria CM, et al. Healthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age. Circulation 2012; 125:994-1004. Abstract.

Ford ES, Greenlund KJ, Hong Y. Ideal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United States. Circulation 2012; 125:987-995. Abstract.

]]> Fri, 20 Apr 2012 13:50:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/VkRzO-5apms/the-us-postal-service-promotes-heart-health http://blogs.theheart.org/clot-blog/2012/4/20/the-us-postal-service-promotes-heart-health http://blogs.theheart.org/clot-blog/2012/4/20/the-us-postal-service-promotes-heart-health#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/the-us-postal-service-promotes-heart-health.jpg 0 http://blogs.theheart.org/clot-blog/2012/4/20/the-us-postal-service-promotes-heart-health Thrombolysis in acute pulmonary embolism: An update with Dr Stavros Konstantinides Clotblog with Dr Samuel Goldhaber info@theheart.org As enrollment for his trial reaches completion, Dr Stavros Konstantinides discusses thrombolysis in submassive pulmonary embolism and his thoughts on how the findings might impact guidelines.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/b2xHd2203jw" height="1" width="1"/> As enrollment for his trial reaches completion, Dr Stavros Konstantinides discusses thrombolysis in submassive pulmonary embolism and his thoughts on what impact the findings might have on guidelines.

See also:

Stein PD, Matta F, Steinberger DS, et al. Intracerebral hemorrage with thrombolytic therapy for acute pulmonary embolism. Am J Med 2012; 125:50-56. Abstract.

Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: Saves lives but underused. Am J Med 2012. Abstract.

EINSTEIN PE: Rivaroxaban equals standard therapy, halves major bleeding

Novel anticoagulants in AF: A guide for the clinical practitioner

]]> Wed, 04 Apr 2012 15:08:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/b2xHd2203jw/thrombolysis-in-acute-thromboembolism-an-update-with-dr-stavros-konstantinides http://blogs.theheart.org/clot-blog/2012/4/4/thrombolysis-in-acute-thromboembolism-an-update-with-dr-stavros-konstantinides http://blogs.theheart.org/clot-blog/2012/4/4/thrombolysis-in-acute-thromboembolism-an-update-with-dr-stavros-konstantinides#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/thrombolysis-in-acute-thromboembolism-an-update-with-dr-stavros-konstantinides.jpg 0 acc 2012 acc 2012 http://blogs.theheart.org/clot-blog/2012/4/4/thrombolysis-in-acute-thromboembolism-an-update-with-dr-stavros-konstantinides Einstein PE: Rivaroxaban shines as viable monotherapy for pulmonary embolism Clotblog with Dr Samuel Goldhaber info@theheart.org With the results of the EINSTEIN PE trial, here at the ACC meeting in Chicago, 2012 will be remembered as the landmark year when rivaroxaban was shown to be a viable monotherapy treatment for a broad spectrum of patients with acute pulmonary embolism.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/TQJKPFxJcj4" height="1" width="1"/> 1954 stands out in our memories as the year that warfarin was introduced for the treatment of arterial venous thromboembolism. With the results of the EINSTEIN PE trial, here at the ACC meeting in Chicago, 2012 will be remembered as the landmark year when rivaroxaban was shown to be a viable monotherapy treatment for a broad spectrum of patients with acute pulmonary embolism.

See also:

]]> Mon, 26 Mar 2012 10:25:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/TQJKPFxJcj4/einstein-pe-rivaroxaban-shines-as-viable-monotherapy-for-pulmonary-embolism http://blogs.theheart.org/clot-blog/2012/3/26/einstein-pe-rivaroxaban-shines-as-viable-monotherapy-for-pulmonary-embolism http://blogs.theheart.org/clot-blog/2012/3/26/einstein-pe-rivaroxaban-shines-as-viable-monotherapy-for-pulmonary-embolism#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/einstein-pe-rivaroxaban-shines-as-viable-monotherapy-for-pulmonary-embolism.jpg 1 acc 2012 acc 2012 http://blogs.theheart.org/clot-blog/2012/3/26/einstein-pe-rivaroxaban-shines-as-viable-monotherapy-for-pulmonary-embolism Methods to improve medication adherence Clotblog with Dr Samuel Goldhaber info@theheart.org Piazza et al's recent study, which focused on patient education, is a starting point for improving adherence to medication, but the onus should be on drug manufacturers to devise innovative methods to promote adherence to their medications.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/hF7zTXYBWUg" height="1" width="1"/> Piazza et al's recent study, which focused on patient education, is a starting point for improving adherence to medication, but the onus should be on drug manufacturers to devise innovative methods to promote adherence to their medications.

See also:

Piazza G, Nguyen TN, Morrison R, et al. Patient education program for venous thromboembolism prevention in hospitalized patients. Am J Med 2012; 125:258-264. Abstract.

Fanikos J, Piazza G, Zayaruzny M, et al. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost 2009; 102:688-693. Abstract.

]]> Fri, 23 Mar 2012 17:35:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/hF7zTXYBWUg/methods-to-improve-medication-adherence http://blogs.theheart.org/clot-blog/2012/3/20/methods-to-improve-medication-adherence http://blogs.theheart.org/clot-blog/2012/3/20/methods-to-improve-medication-adherence#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/methods-to-improve-medication-adherence.jpg 2 http://blogs.theheart.org/clot-blog/2012/3/20/methods-to-improve-medication-adherence Henrietta Lacks and the HeLa cell (or how to profit from someone else's cancer cells) Clotblog with Dr Samuel Goldhaber info@theheart.org Rebecca Skloot's Immortal Life of Henrietta Lacks is a gripping work that shines light on a murky chapter in the history of American medicine while raising important ethical questions pertaining to race, profit, and medical research.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/v8GP3r_8T1k" height="1" width="1"/> Rebecca Skloot's Immortal Life of Henrietta Lacks is a gripping work that shines light on a murky chapter in the history of American medicine while raising important ethical questions pertaining to race, profit, and medical research.

What are your thoughts on The Immortal Life of Henrietta Lack?

See also:

About The Immortal Life of Henrietta Lacks

]]> Fri, 16 Mar 2012 09:30:00 -0400 http://feedproxy.google.com/~r/clot-blog/~3/v8GP3r_8T1k/henrietta-lacks-and-the-hela-cell-or-how-to-profit-from-someone-else-s-cancer-cells http://blogs.theheart.org/clot-blog/2012/3/14/henrietta-lacks-and-the-hela-cell-or-how-to-profit-from-someone-else-s-cancer-cells http://blogs.theheart.org/clot-blog/2012/3/14/henrietta-lacks-and-the-hela-cell-or-how-to-profit-from-someone-else-s-cancer-cells#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/henrietta-lacks-and-the-hela-cell-or-how-to-profit-from-someone-else-s-cancer-cells.jpg 6 http://blogs.theheart.org/clot-blog/2012/3/14/henrietta-lacks-and-the-hela-cell-or-how-to-profit-from-someone-else-s-cancer-cells Reducing risk of VTE with emotional well-being Clotblog with Dr Samuel Goldhaber info@theheart.org A recent Norwegian study—which underlines the role of emotional well-being to lower risk for VTE—mirrors similar studies on psychological welfare and outcomes in ACS patients.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/tl_zTRywRKc" height="1" width="1"/> A recent Norwegian study—which underlines the role of emotional well-being to lower risk for VTE—mirrors similar studies on psychological welfare and outcomes in ACS patients. This is another reminder to treat VTE and ACS as symptoms of the same vascular disease, rather than as separate entities.

Does your clinical experience concur with the results of this study? Do your happier patients fare better than those who are less emotionally balanced?

See also:

Enga KF, Brækkan SK, Hansen-Krone IJ, et al. Emotional states and future risk of venous thromboembolism. The Tromsø Study. Thromb Haemost 2012; 107:485-493. Abstract.

]]> Fri, 09 Mar 2012 10:30:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/tl_zTRywRKc/reducing-risk-of-vte-with-emotional-wellbeing http://blogs.theheart.org/clot-blog/2012/3/7/reducing-risk-of-vte-with-emotional-wellbeing http://blogs.theheart.org/clot-blog/2012/3/7/reducing-risk-of-vte-with-emotional-wellbeing#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/reducing-risk-of-vte-with-emotional-wellbeing.jpg 0 http://blogs.theheart.org/clot-blog/2012/3/7/reducing-risk-of-vte-with-emotional-wellbeing INR testing in stable patients: Time to decrease frequency? Clotblog with Dr Samuel Goldhaber info@theheart.org Dr Sam Schulman's recent study calls into question the need to test INR every four weeks in stable patients. It's costly and perhaps unwarranted, as indicated by his data, which showed testing on a 12-week cycle to be noninferior to the standard practice.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/sTvGCpxvLf4" height="1" width="1"/> Dr Sam Schulman's recent study calls into question the need to test INR every four weeks in stable patients. It's costly and perhaps unwarranted, as indicated by his data, which showed testing on a 12-week cycle to be noninferior to the standard practice. Is it now appropriate to consider relaxing the frequency of INR testing in this set of patients? What are your thoughts?

See also:

Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios. Ann Intern Med 2011; 155:653-659. Available here.

Fewer INR checks safe in patients on stable-dose warfarin

]]> Fri, 02 Mar 2012 09:30:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/sTvGCpxvLf4/inr-testing-in-stable-patients-time-to-decrease-frequency http://blogs.theheart.org/clot-blog/2012/2/29/inr-testing-in-stable-patients-time-to-decrease-frequency http://blogs.theheart.org/clot-blog/2012/2/29/inr-testing-in-stable-patients-time-to-decrease-frequency#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/inr-testing-in-stable-patients-time-to-decrease-frequency.jpg 5 http://blogs.theheart.org/clot-blog/2012/2/29/inr-testing-in-stable-patients-time-to-decrease-frequency CHEST/ACCP 2012 guidelines: What's new? Clotblog with Dr Samuel Goldhaber info@theheart.org For the ninth edition, the American College of Chest Physicians' (ACCP) antithrombotic guidelines have been overhauled, slimming down to 70 pages of succinct bottom-line recommendations.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/y-B3wWVelJA" height="1" width="1"/> For the ninth edition, the American College of Chest Physicians' (ACCP) antithrombotic guidelines have been overhauled, slimming down to 70 pages of succinct bottom-line recommendations. Find out more.

See also:

Chest 2012; 141(2):1S-70S. Available here.

New ACCP thrombosis guidelines offer weak support for aspirin in primary prevention

]]> Fri, 24 Feb 2012 07:45:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/y-B3wWVelJA/chest-accp-2012-guidelines-what-s-new http://blogs.theheart.org/clot-blog/2012/2/21/chest-accp-2012-guidelines-what-s-new http://blogs.theheart.org/clot-blog/2012/2/21/chest-accp-2012-guidelines-what-s-new#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/chest-accp-2012-guidelines-what-s-new.jpg 3 http://blogs.theheart.org/clot-blog/2012/2/21/chest-accp-2012-guidelines-what-s-new RACE-2: Relaxing rate control in patients with permanent AF Clotblog with Dr Samuel Goldhaber info@theheart.org The RACE-2 trial challenges standard practice for patients with permanent atrial fibrillation by showing equal quality of life for patients whose target heart rate is a more lenient 120 bpm vs the standard goal of 80 bpm.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/riz33m64HjA" height="1" width="1"/> The RACE-2 trial challenges standard practice for patients with permanent atrial fibrillation by showing equal quality of life for patients whose target heart rate is a more lenient 120 bpm vs the standard goal of 80 bpm.

Have you modified your practice based on these results?

See also:

Groenvold HF, Crijns HJGM, Van den berg MP, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation. JACC 2011;58:1795-803. Abstract.

RACE-2: "Lenient" rate control for AF doesn't compromise quality of life

]]> Fri, 17 Feb 2012 09:30:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/riz33m64HjA/race2-relaxing-rate-control-in-patients-with-permanent-af http://blogs.theheart.org/clot-blog/2012/2/17/race2-relaxing-rate-control-in-patients-with-permanent-af http://blogs.theheart.org/clot-blog/2012/2/17/race2-relaxing-rate-control-in-patients-with-permanent-af#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/race2-relaxing-rate-control-in-patients-with-permanent-af.jpg 0 http://blogs.theheart.org/clot-blog/2012/2/17/race2-relaxing-rate-control-in-patients-with-permanent-af Preventing postthrombotic syndrome: CAVENT supports the "open vein hypothesis" Clotblog with Dr Samuel Goldhaber info@theheart.org CAVENT, a recently published Norwegian study, showed a statistically significant decrease in rates of postthrombotic syndrome two years post-DVT event among patients who underwent catheter-based thrombolysis compared with those treated with a standard reg<img src="http://feeds.feedburner.com/~r/clot-blog/~4/PCRVuYkRZf4" height="1" width="1"/> CAVENT, a recently published Norwegian study, showed a statistically significant decrease in rates of postthrombotic syndrome two years post-DVT event among patients who underwent catheter-based thrombolysis compared with those treated with a standard regimen of anticoagulation. Will the ATTRACT study—which is currently enrolling—give further credence to the longstanding "open-vein hypothesis"?

See also:

Enden T, Haig Y, Klow N, et al. Long-term outcomes after additional catheter-directed thrombolysis versus standard treatment for acute iliofemeral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2011; 379:31-38. Abstract.

Catheter-directed thrombolysis in iliofemoral DVT reduces risk of postthrombotic syndrome

]]> Fri, 10 Feb 2012 09:20:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/PCRVuYkRZf4/preventing-postthrombotic-syndrome-cavent-supports-the-open-vein-hypothesis http://blogs.theheart.org/clot-blog/2012/2/10/preventing-postthrombotic-syndrome-cavent-supports-the-open-vein-hypothesis http://blogs.theheart.org/clot-blog/2012/2/10/preventing-postthrombotic-syndrome-cavent-supports-the-open-vein-hypothesis#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/preventing-postthrombotic-syndrome-cavent-supports-the-open-vein-hypothesis.jpg 3 http://blogs.theheart.org/clot-blog/2012/2/10/preventing-postthrombotic-syndrome-cavent-supports-the-open-vein-hypothesis IVC filters: The genie's out of the bottle Clotblog with Dr Samuel Goldhaber info@theheart.org The placement of inferior vena cava (IVC) filters has grown exponentially in the US, with up to 20% of these being placed in inappropriate patients.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/psl3Idt2rLw" height="1" width="1"/> The placement of inferior vena cava (IVC) filters has grown exponentially in the US, with up to 20% of these being placed in inappropriate patients. As we balance the benefit vs risk for this procedure and evaluate cost, Dr Paul Stein's proposed randomized trial will help us to see more clearly.

See also:

Stein PD, Matta F, Huss RD. Increasing use of vena cava filters for prevention of pulmonary embolism. Am J Med 2011; 124:655-661. Abstract.

]]> Fri, 03 Feb 2012 08:30:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/psl3Idt2rLw/ivc-filters-the-genie-s-out-of-the-bottle http://blogs.theheart.org/clot-blog/2012/2/2/ivc-filters-the-genie-s-out-of-the-bottle http://blogs.theheart.org/clot-blog/2012/2/2/ivc-filters-the-genie-s-out-of-the-bottle#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/ivc-filters-the-genie-s-out-of-the-bottle.jpg 0 http://blogs.theheart.org/clot-blog/2012/2/2/ivc-filters-the-genie-s-out-of-the-bottle Emergency hospitalization from adverse drug events: Warfarin the biggest culprit Clotblog with Dr Samuel Goldhaber info@theheart.org In the US warfarin is by far the greatest cause of adverse drug events leading to emergency hospitalization.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/hOgHeZi-gRw" height="1" width="1"/> In the US warfarin is by far the greatest cause of adverse drug events leading to emergency hospitalization. This is another reason to ensure that patients are following the most appropriate anticoagulation regimen and that they are closely followed for safety.

See also:

Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans.  N ngl J Med 2011; 365:2002-2012. Abstract.

Warfarin tops list for emergency hospitalizations in seniors

 

]]> Fri, 27 Jan 2012 08:50:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/hOgHeZi-gRw/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit http://blogs.theheart.org/clot-blog/2012/1/26/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit http://blogs.theheart.org/clot-blog/2012/1/26/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit.jpg 0 http://blogs.theheart.org/clot-blog/2012/1/26/emergency-hospitalization-from-adverse-drug-events-warfarin-the-biggest-culprit Self-monitoring INR and self-managing warfarin to reduce thromboembolic events Clotblog with Dr Samuel Goldhaber info@theheart.org A recent study published in the Lancet reports a 50% reduction in thromboembolic events among patients who self-monitor their INR and self-manage their warfarin dosing. Why aren't these practices more common?<img src="http://feeds.feedburner.com/~r/clot-blog/~4/sh0IL99G4MM" height="1" width="1"/> A recent study published in the Lancet reports a 50% reduction in thromboembolic events among patients who self-monitor their INR and self-manage their warfarin dosing. Why aren't these practices more common?

See also:

Anticoagulation self-monitoring halves thromboembolic risk  

Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data.  Lancet 2011; DOI:10.1016/S0140-6736(11)61294-4. Abstract.

]]> Fri, 20 Jan 2012 07:30:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/sh0IL99G4MM/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events http://blogs.theheart.org/clot-blog/2012/1/18/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events http://blogs.theheart.org/clot-blog/2012/1/18/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events.jpg 5 http://blogs.theheart.org/clot-blog/2012/1/18/selfmonitoring-inr-and-selfmanaging-warfarin-to-reduce-thromboembolic-events LIFENOX: No advantage of VTE prophylaxis in hospitalized medical service patients Clotblog with Dr Samuel Goldhaber info@theheart.org The surprising results of the LIFENOX trial--which failed to show an advantage of daily enoxaparin vs placebo to reduce mortality in the acute-care setting--challenge dogma. What explains these results?<img src="http://feeds.feedburner.com/~r/clot-blog/~4/9dbZqSZ5uc0" height="1" width="1"/> The surprising results of the LIFENOX trial—which failed to show an advantage of daily enoxaparin vs placebo to reduce mortality in the acute-care setting—challenge dogma. What explains these results?

See also:

Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2012; 365:2463-2472. Abstract.

Enoxaparin prophylaxis doesn't cut mortality in acute-care setting

]]> Fri, 13 Jan 2012 09:20:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/9dbZqSZ5uc0/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients http://blogs.theheart.org/clot-blog/2012/1/9/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients http://blogs.theheart.org/clot-blog/2012/1/9/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients.jpg 1 http://blogs.theheart.org/clot-blog/2012/1/9/lifenox-no-advantage-of-vte-prophylaxis-in-hospitalized-medical-service-patients Focus on pulmonary arterial hypertension and the right ventricle at the Cardiology Society of Mexico Clotblog with Dr Samuel Goldhaber info@theheart.org Focus on pulmonary arterial hypertension and the right ventricle at the Cardiology Society of Mexico<img src="http://feeds.feedburner.com/~r/clot-blog/~4/Xvq35KiTLEM" height="1" width="1"/> Dr Samuel Goldhaber recently sat down with Dr Julio Sandoval to discuss the challenges and rewards of coordinating the scientific committee at the recent Cardiology Society of Mexico annual meeting in Puerto Vallarta.

To read an English-language translation of this Spanish discussion, click here.

]]> Fri, 06 Jan 2012 09:10:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/Xvq35KiTLEM/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico http://blogs.theheart.org/clot-blog/2011/12/23/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico http://blogs.theheart.org/clot-blog/2011/12/23/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico.jpg 0 http://blogs.theheart.org/clot-blog/2011/12/23/focus-on-pulmonary-arterial-hypertension-and-the-right-ventricle-at-the-cardiology-society-of-mexico Celebrating 75-years of the Cardiology Society of Mexico with Dr Carlos Martínez Sánchez Clotblog with Dr Samuel Goldhaber info@theheart.org As the Cardiology Society of Mexico celebrated an important anniversary in Puerto Vallarta, Dr Samuel Goldhaber caught up with the society's president. Find out about the society, its constituents, and regional challenges.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/wnLtyd4R6SQ" height="1" width="1"/> As the Cardiology Society of Mexico celebrated an important anniversary in Puerto Vallarta, Dr Samuel Goldhaber caught up with the society's president. Find out about the society, its constituents, and regional challenges.

To read an English-language translation of this Spanish discussion, click here.

]]> Fri, 23 Dec 2011 08:00:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/wnLtyd4R6SQ/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez http://blogs.theheart.org/clot-blog/2011/12/19/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez http://blogs.theheart.org/clot-blog/2011/12/19/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez.jpg 0 http://blogs.theheart.org/clot-blog/2011/12/19/celebrating-75years-of-the-cardiology-society-of-mexico-with-dr-carlos-martnez-snchez Vitamin T and other concerns in Mexican pediatric cardiology with Dr Carlos Zabal Clotblog with Dr Samuel Goldhaber info@theheart.org From the recent annual meeting of the Mexican Cardiology Society, Dr Samuel Goldhaber discusses patent ductus arteriosus, aortic-valve stenosis, and the growing issue of vitamin T overconsumption with Mexican pediatric cardiologist Dr Carlos Zabal.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/AH2SsViKdSw" height="1" width="1"/> From the recent annual meeting of the Mexican Cardiology Society, Dr Samuel Goldhaber discusses patent ductus arteriosus, aortic-valve stenosis, and the growing issue of "vitamin T" overconsumption with Mexican pediatric cardiologist Dr Carlos Zabal.

To read an English-language translation of this Spanish discussion, click here.

]]> Fri, 16 Dec 2011 08:25:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/AH2SsViKdSw/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal http://blogs.theheart.org/clot-blog/2011/12/15/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal http://blogs.theheart.org/clot-blog/2011/12/15/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal.jpg 0 http://blogs.theheart.org/clot-blog/2011/12/15/vitamin-t-and-other-concerns-in-mexican-pediatric-cardiology-with-dr-carlos-zabal Got your Green Book? Clotblog with Dr Samuel Goldhaber info@theheart.org Edited by Marc Sabatine, Pocket Medicine, 4th ed (aka "the Green Book") is a must-have for virtually all healthcare professionals. Its extensive references, organization by subspecialties, algorithms, and photo inserts make it immensely practical.<img src="http://feeds.feedburner.com/~r/clot-blog/~4/SFml4BGcioc" height="1" width="1"/> Edited by Marc Sabatine, Pocket Medicine, 4th ed (aka "the Green Book") is a must-have for virtually all healthcare professionals. Its extensive references, organization by subspecialties, algorithms, and photo inserts make it immensely practical and easy to use.

Do you carry the Green Book or the Washington Manual? Or both?

]]> Mon, 12 Dec 2011 15:05:00 -0500 http://feedproxy.google.com/~r/clot-blog/~3/SFml4BGcioc/got-your-green-book http://blogs.theheart.org/clot-blog/2011/12/6/got-your-green-book http://blogs.theheart.org/clot-blog/2011/12/6/got-your-green-book#comments Clotblog with Dr Samuel Goldhaber http://blogs.theheart.org/images/thumbnails/got-your-green-book.jpg 0 http://blogs.theheart.org/clot-blog/2011/12/6/got-your-green-book